1.1 Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth

1.2 The Strategic Imperative 8™

1.3 The Impact of the Top Three Strategic Imperatives in AI Augmented Molecular Diagnostics

1.4 Growth Opportunities Fuel the Growth Pipeline Engine™

2.1 AI and its Growing Prevalence in Healthcare Applications

2.2 What is Driving Adoption of AI/ ML in Healthcare?

2.3 Evolution of AI in Diagnostics

2.4 Key Applications of AI Tools in Molecular Diagnostics

2.5 Research Context

2.6 Research Scope—Key Questions Addressed

2.7 Research Methodology

2.8 Key Findings

3.1 Molecular Diagnostics—Challenges and Needs

3.2 How can AI Accentuate Molecular Diagnostics?

3.3 AI Augmentation to Improve Predictive, Diagnostic, and Prognostic Capabilities of Molecular Diagnostics

3.4 Data Science-Technology Architecture in Molecular Diagnostics

3.5 Applications of AI in Molecular Diagnostics

3.6 Challenges in the Adoption of AI in Molecular Diagnostics

4.1 Applications in Infectious Disease Testing

4.2 Key Stakeholders Developing AI-Augmented Infectious Disease Dx

4.3 Infectious Disease Testing—AI and Opportunities

4.4 Applications in Oncology Diagnostics

4.5 Key Stakeholders Developing AI-Augmented Liquid Biopsies

4.6 Applications in Precision Medicine

4.7 Key Stakeholders Developing AI-Augmented Precision Diagnostics

4.8 How can AI Accentuate Molecular Diagnostics?

4.9 Role of AI in Cancer Molecular Diagnostics

4.10 Applications in Rare Disease Testing

5.1 Strategic Collaboration to Advance AI Molecular Dx

5.2 Funding Analysis of AI- and ML-based Molecular Diagnostics Companies, Jan. 2016─Sept. 2021

5.3 Support for Geographic Expansion and Commercialization from Late-stage Private Funding

5.3 Support for Geographic Expansion and Commercialization from Late-stage Private Funding (continued)

5.3 Support for Geographic Expansion and Commercialization from Late-stage Private Funding (continued)

6.1 GRAIL, Inc.

6.2 Diagnostics.ai

6.3 Sophia Genetics

6.4 Elypta AB

6.5 Freenomemultiomics liquid biopsy for early cancer detection

6.6 Cambridge Cancer Genomics (Dante Labs S.r.l.)

6.7 Immunis.ai

6.8 Amwise Diagnostic Pvt. Ltd.

6.9 Billiontoone

7.1 Growth Opportunity 1: Assay-agnostic, Flexible AI Analytics Platform for Molecular Diagnostics Democratization

7.1 Growth Opportunity 1: Assay-agnostic, Flexible AI Analytics Platform for Molecular Diagnostics Democratization (continued)

7.2 Growth Opportunity 2: AI-enabled Large-scale Genomic Surveillance and Convergence of AI and Big Data for Greater Preparedness

7.2 Growth Opportunity 2: AI-enabled Large-scale Genomic Surveillance and Convergence of AI and Big Data for Greater Preparedness (continued)

7.3 Growth Opportunity 3: AI for Maximum Potential of Multimodal Data

7.3 Growth Opportunity 3: AI for Maximum Potential of Multimodal Data (continued)

7.4 Growth Opportunity 4: AI/ML for RNA Sequencing Applications

7.4 Growth Opportunity 4: Apply AI/ML To RNA Sequencing (continued)

8.1 Technology Readiness Levels (TRL): Explanation

9.1 Your Next Steps

9.2 Why Frost, Why Now?

Legal Disclaimer